Literature DB >> 16806792

Overexpression of RhoA is associated with poor prognosis in hepatocellular carcinoma.

X R Li1, F Ji, J Ouyang, W Wu, L Y Qian, K Y Yang.   

Abstract

AIMS: The aim of this study was to investigate the relationship between RhoA expression and clinic pathological parameters of hepatocellular carcinoma (HCC), and to evaluate the prognostic value of RhoA for HCC patients.
METHODS: Three methods, including reverse transcription and polymerase chain reaction, Western blot and immunohistochemical staining were employed to detect RhoA expression in 128 HCC specimens. The correlation between RhoA expression and clinicopathologic outcome, and prognostic value of RhoA for HCC patients were analyzed.
RESULTS: HCC tissues revealed significantly higher levels of both RhoA mRNA and protein than pericarcinomatous liver tissues (PCLT) (P=0.001). The mRNA and protein expression levels of RhoA in HCC tissues showed strongly positive correlation (correlation coefficient=0.712, P=0.01). There was significant correlation among RhoA mRNA and protein overexpression, and venous invasion (P=0.009 and P=0.040, respectively) and cell differentiation (P=0.021 and P=0.017). HCC patients with RhoA-positive expression showed a significantly poor prognosis than those with RhoA-negative expression (P=0.039).
CONCLUSIONS: Our data strongly suggested that increased RhoA expression in HCC correlated with venous invasion and cell differentiation of HCC, overexpression of RhoA indicated a poor prognosis in HCC patients.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16806792     DOI: 10.1016/j.ejso.2006.05.012

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  28 in total

1.  HGF/c-Met overexpressions, but not met mutation, correlates with progression of non-small cell lung cancer.

Authors:  Mukaddes Gumustekin; Aydanur Kargi; Gulay Bulut; Aysim Gozukizil; Cagnur Ulukus; Ilhan Oztop; Nese Atabey
Journal:  Pathol Oncol Res       Date:  2011-07-21       Impact factor: 3.201

2.  The Correlation Between RhoA Expression and Clinicopathological Characteristics in Gastric Cancer Patients After Curative Surgery.

Authors:  Kuo-Hung Huang; Yuan-Tzu Lan; Ming-Huang Chen; Yee Chao; Su-Shun Lo; Anna Fen-Yau Li; Chew-Wun Wu; Shih-Hwa Chiou; Muh-Hwa Yang; Yi-Ming Shyr; Wen-Liang Fang
Journal:  World J Surg       Date:  2015-09       Impact factor: 3.352

Review 3.  Targeting the mevalonate cascade as a new therapeutic approach in heart disease, cancer and pulmonary disease.

Authors:  Behzad Yeganeh; Emilia Wiechec; Sudharsana R Ande; Pawan Sharma; Adel Rezaei Moghadam; Martin Post; Darren H Freed; Mohammad Hashemi; Shahla Shojaei; Amir A Zeki; Saeid Ghavami
Journal:  Pharmacol Ther       Date:  2014-02-26       Impact factor: 12.310

4.  Silencing of RhoA and RhoC expression by RNA interference suppresses human colorectal carcinoma growth in vivo.

Authors:  Haibo Wang; Gang Zhao; Xiangping Liu; Aihua Sui; Kun Yang; Ruyong Yao; Zongbao Wang; Qiang Shi
Journal:  J Exp Clin Cancer Res       Date:  2010-09-09

5.  Rac and Rho GTPases in cancer cell motility control.

Authors:  Matteo Parri; Paola Chiarugi
Journal:  Cell Commun Signal       Date:  2010-09-07       Impact factor: 5.712

6.  Effect of shRNA targeted against RhoA on proliferation and migration of human colonic cancer cells.

Authors:  Man Wang; Xiu-Jie Wang; Bing-Rong Liu
Journal:  Int J Clin Exp Pathol       Date:  2015-06-01

7.  Noncanonical Wnt11 inhibits hepatocellular carcinoma cell proliferation and migration.

Authors:  Takashi Toyama; Han Chu Lee; Hironori Koga; Jack R Wands; Miran Kim
Journal:  Mol Cancer Res       Date:  2010-01-26       Impact factor: 5.852

8.  RhoB is regulated by hypoxia and modulates metastasis in breast cancer.

Authors:  Julia A Ju; Inês Godet; Josh W DiGiacomo; Daniele M Gilkes
Journal:  Cancer Rep (Hoboken)       Date:  2019-02-11

9.  The leukemia-associated Rho guanine nucleotide exchange factor LARG is required for efficient replication stress signaling.

Authors:  Ryan D Beveridge; Christopher J Staples; Abhijit A Patil; Katie N Myers; Sarah Maslen; J Mark Skehel; Simon J Boulton; Spencer J Collis
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

Review 10.  Rho GTPases modulate malignant transformation of tumor cells.

Authors:  Jose L Orgaz; Cecilia Herraiz; Victoria Sanz-Moreno
Journal:  Small GTPases       Date:  2014-05-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.